Page last updated: 2024-11-05

trifluoperazine and Metastase

trifluoperazine has been researched along with Metastase in 2 studies

Research Excerpts

ExcerptRelevanceReference
"Twenty patients with metastatic breast cancer were treated every 3 weeks with TFP 5 mg by mouth every 6 hours on days 0-5 and doxorubicin 60 mg/m2/96 hr on days 1-4 by continuous intravenous infusion."6.67Phase II trial of doxorubicin and trifluoperazine in metastatic breast cancer. ( Bauer, L; Budd, GT; Bukowski, RM; Ganapathi, R; Lichtin, A; Van Kirk, P, 1993)
"Twenty patients with metastatic breast cancer were treated every 3 weeks with TFP 5 mg by mouth every 6 hours on days 0-5 and doxorubicin 60 mg/m2/96 hr on days 1-4 by continuous intravenous infusion."2.67Phase II trial of doxorubicin and trifluoperazine in metastatic breast cancer. ( Bauer, L; Budd, GT; Bukowski, RM; Ganapathi, R; Lichtin, A; Van Kirk, P, 1993)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kang, S1
Hong, J1
Lee, JM1
Moon, HE1
Jeon, B1
Choi, J1
Yoon, NA1
Paek, SH1
Roh, EJ1
Lee, CJ1
Kang, SS1
Budd, GT1
Bukowski, RM1
Lichtin, A1
Bauer, L1
Van Kirk, P1
Ganapathi, R1

Trials

1 trial available for trifluoperazine and Metastase

ArticleYear
Phase II trial of doxorubicin and trifluoperazine in metastatic breast cancer.
    Investigational new drugs, 1993, Volume: 11, Issue:1

    Topics: Adult; Breast Neoplasms; Doxorubicin; Drug Resistance; Drug Therapy, Combination; Female; Humans; Mi

1993

Other Studies

1 other study available for trifluoperazine and Metastase

ArticleYear
Trifluoperazine, a Well-Known Antipsychotic, Inhibits Glioblastoma Invasion by Binding to Calmodulin and Disinhibiting Calcium Release Channel IP3R.
    Molecular cancer therapeutics, 2017, Volume: 16, Issue:1

    Topics: Animals; Antineoplastic Agents; Calcium; Calmodulin; Cell Line, Tumor; Cell Movement; Cell Survival;

2017